ST. PAUL, Minn. and HOLLISTON, Mass., June 13, 2018 (GLOBE NEWSWIRE) -- Data Sciences International (DSI), a subsidiary of Harvard Bioscience, Inc. (Nasdaq:HBIO) launched a new inhalation and exposure system to meet the evolving needs of researchers.
Jeffrey Duchemin, President and CEO of Harvard Bioscience said, “Delivering drugs to the lungs is gaining in popularity for a variety of systemic diseases.” He continued, “Our expertise in respiratory instrumentation technology uniquely positions us in this rapidly growing market."
The U.S. Food & Drug Administration and pharmaceutical companies are placing an increased focus on inhalation as a method for drug administration over the more traditional ingestion method for both respiratory and systemic diseases. The market for these types of drugs is approximately $48 billion.1 With inhalation delivery, less drug is needed to be effective, reducing the risk of side effects.2 DSI’s inhalation exposure system can assist in the development of these drugs as well as numerous other applications including development of animal models and testing of products, biological threats, and environmental pollutants.
About Data Sciences International
Data Sciences International (DSI) provides a complete preclinical platform to assess physiological data for research ranging from basic, to drug discovery, and drug development. DSI is the leading provider of telemetry systems, pulmonary solutions, associated software platforms, and services. DSI is a subsidiary of Harvard Bioscience (Nasdaq:HBIO) a global developer, manufacturer, and marketer of a broad range of specialized products for life science research. For more information, please visit our website at www.datasci.com.
1Pulmatrix Inc. (2016). “Pulmatrix Highlights Recent Report Predicting Rapid Growth for Inhaled Drug Delivery Methods”. https://ir.pulmatrix.com/2016-09-23-Pulmatrix-Highlights-Recent-Report-Predicting-Rapid-Growth-for-Inhaled-Drug-Delivery-Methods
2Moore S. (2017). “Looking to the Future – The Route for Inhaled Medications and Inhalation Technology”. https://www.pharmoutsourcing.com/Featured-Articles/345029-Looking-to-the-Future-The-Route-for-Inhaled-Medications-and-Inhalation-Technology/